These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 1721397

  • 1. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient.
    Freise CE, Rowley H, Lake J, Hebert M, Ascher NL, Roberts JP.
    Transplant Proc; 1991 Dec; 23(6):3173-4. PubMed ID: 1721397
    [No Abstract] [Full Text] [Related]

  • 2. Neurotoxicity of FK 506 in liver transplant recipients.
    Frank B, Perdrizet GA, White HM, Marsh JW, Lemann W, Woodle ES.
    Transplant Proc; 1993 Apr; 25(2):1887-8. PubMed ID: 7682355
    [No Abstract] [Full Text] [Related]

  • 3. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
    Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Lobeck H, Hop U, Neuhaus P.
    Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
    [No Abstract] [Full Text] [Related]

  • 5. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB.
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [Abstract] [Full Text] [Related]

  • 6. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man.
    Söderdahl G, Groth CG, Angelin B, Duraj F, Einarsson K, Ericzon BG.
    Transplant Proc; 1995 Feb; 27(1):1125. PubMed ID: 7533362
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 8. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506.
    Lopez OL, Martinez AJ, Torre-Cisneros J.
    Transplant Proc; 1991 Dec; 23(6):3181-2. PubMed ID: 1721400
    [No Abstract] [Full Text] [Related]

  • 9. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.
    Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R.
    Transplant Proc; 1991 Dec; 23(6):3153-5. PubMed ID: 1721389
    [No Abstract] [Full Text] [Related]

  • 10. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
    Bechstein WO, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Ericzon BG, Bismuth H.
    Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
    [No Abstract] [Full Text] [Related]

  • 11. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine.
    Armstrong VW, Kaltefleiter M, Luy-Kaltefleiter M, Schütz E, Wieland E, Loss M, Winkler M, Ringe B, Oellerich M.
    Transplant Proc; 1995 Feb; 27(1):1201-3. PubMed ID: 7533371
    [No Abstract] [Full Text] [Related]

  • 12. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC, Theilmann L.
    Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
    [No Abstract] [Full Text] [Related]

  • 13. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group.
    Ochiai T, Fukao K, Takahashi K, Endo T, Oshima S, Uchida K, Yokoyama I, Ishibashi M, Takahara S, Iwasaki Y.
    Transplant Proc; 1995 Feb; 27(1):829-33. PubMed ID: 7533435
    [No Abstract] [Full Text] [Related]

  • 14. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine.
    Park KM, Hay JE, Lee SG, Lee YJ, Wiesner RH, Porayko MK, Krom RA.
    Transplant Proc; 1996 Jun; 28(3):1738-40. PubMed ID: 8658863
    [No Abstract] [Full Text] [Related]

  • 15. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.
    Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, Takaya S, Alessiani M, Demetris A, Bronster O.
    Transplant Proc; 1991 Dec; 23(6):2977-83. PubMed ID: 1721333
    [No Abstract] [Full Text] [Related]

  • 16. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
    Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Wahlstrom HE, Sanchez-Urdazpal L, Richards T, Crotty P, Beaver S.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
    [No Abstract] [Full Text] [Related]

  • 17. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A.
    Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmüller T, Christe W, Hopf U, Lobeck H, Neuhaus P.
    Transplant Proc; 1995 Feb; 27(1):1117-20. PubMed ID: 7533359
    [No Abstract] [Full Text] [Related]

  • 18. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.
    Neal DA, Gimson AE, Gibbs P, Alexander GJ.
    Liver Transpl; 2001 Jun; 7(6):533-9. PubMed ID: 11443583
    [Abstract] [Full Text] [Related]

  • 19. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES, So S, Jendrisak MD, Perdrizet GA, White HM, Marsh JW.
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract] [Full Text] [Related]

  • 20. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients.
    Felser I, Wagner S, Depee J, Johnson N, Staschak S, Jain A, Fung JJ, Starzl TE.
    Transplant Proc; 1991 Dec; 23(6):3032-4. PubMed ID: 1721350
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.